|
1
|
Cao W, Chen HD, Yu YW, Li N and Chen WQ:
Changing profiles of cancer burden worldwide and in China: A
secondary analysis of the global cancer statistics 2020. Chin Med J
(Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gang H, Jingyi G, Shujiang R, Xiaobin L
and Fenli L: Advances in breast cancer treatment. J Front Med.
10:11–12. 2020.(In Chinese).
|
|
3
|
Long Y, Pan Z, Wenhua Z and Jingzhi G:
Progress in the key enzymes in tumor lipid metabolism. Cancer Res
Clin. 28:789–792. 2016.(In Chinese).
|
|
4
|
Röhrig F and Schulze A: The multifaceted
roles of fatty acid synthesis in cancer. Nat Rev Cancer.
16:732–749. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maan M, Peters JM, Dutta M and Patterson
AD: Lipid metabolism and lipophagy in cancer. Biochem Biophys Res
Commun. 504:582–589. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bian X, Liu R, Meng Y, Xing D, Xu D and Lu
Z: Lipid metabolism and cancer. J Exp Med. 218:e202016062021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beloribi-Djefaflia S, Vasseur S and
Guillaumond F: Lipid metabolic reprogramming in cancer cells.
Oncogenesis. 5:e1892016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Halama A, Guerrouahen BS, Pasquier J,
Satheesh NJ, Suhre K and Rafii A: Nesting of colon and ovarian
cancer cells in the endothelial niche is associated with
alterations in glycan and lipid metabolism. Sci Rep. 7:399992017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kouba S, Ouldamer L, Garcia C, Fontaine D,
Chantome A, Vandier C, Goupille C and Potier-Cartereau M: Lipid
metabolism and calcium signaling in epithelial ovarian cancer. Cell
Calcium. 81:38–50. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sung H, Siegel RL, Torre LA,
Pearson-Stuttard J, Islami F, Fedewa SA, Goding Sauer A, Shuval K,
Gapstur SM, Jacobs EJ, et al: Global patterns in excess body weight
and the associated cancer burden. CA Cancer J Clin. 69:88–112.
2019.PubMed/NCBI
|
|
11
|
Lingquan K, Xin L, Hongyuan L, Guosheng R
and Kainan W: Progress on the study of breast cancer related
dyslipidemia. Chin J Endocrine Surg. 11:89–91. 962017.
|
|
12
|
Nelson ER: The significance of cholesterol
and its metabolite, 27-hydroxycholesterol in breast cancer. Mol
Cell Endocrinol. 466:73–80. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Quiroga-Morales LA, Sat-Muñoz D,
Martínez-Herrera BE, Alcántara-Cadillo RR, Macías-López GG,
García-Cobián TA, Bañuelos-Rizo M and Balderas-Peña LMA: Obesity
and adipocytokines in breast cancer and benign breast disease. Rev
Med Inst Mex Seguro Soc. 56:246–254. 2018.(In Spanish). PubMed/NCBI
|
|
14
|
Qi L, Yanhui Z, Junzhe Y, Xian W, Xingmeng
W, Chaoran Y, Ruyu C and Xiaoan L: Research progress on the
relationship between serum lipid level and breast cancer treatment.
Chin J Surg Oncol. 11:168–171. 2019.(In Chinese).
|
|
15
|
Chen M, Zhao Y, Yang X, Zhao Y, Liu Q, Liu
Y, Hou Y, Sun H and Jin W: NSDHL promotes triple-negative breast
cancer metastasis through the TGFβ signaling pathway and
cholesterol biosynthesis. Breast Cancer Res Treat. 187:349–362.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bustreo S, Osella-Abate S, Cassoni P,
Donadio M, Airoldi M, Pedani F, Papotti M, Sapino A and Castellano
I: Optimal Ki67 cut-off for luminal breast cancer prognostic
evaluation: A large case series study with a long-term follow-up.
Breast Cancer Res Treat. 157:363–371. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goldhirsch A, Wood WC, Coates AS, Gelber
RD, Thürlimann B and Senn HJ; Panel members, : Strategies for
subtypes-dealing with the diversity of breast cancer: Highlights of
the St. Gallen international expert consensus on the primary
therapy of early breast cancer 2011. Ann Oncol. 22:1736–1747. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin NU, Claus E, Sohl J, Razzak AR,
Arnaout A and Winer EP: Sites of distant recurrence and clinical
outcomes in patients with metastatic triple-negative breast cancer:
High incidence of central nervous system metastases. Cancer.
113:2638–2645. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cao MD, Lamichhane S, Lundgren S, Bofin A,
Fjøsne H, Giskeødegård GF and Bathen TF: Metabolic characterization
of triple negative breast cancer. BMC Cancer. 14:9412014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li LT, Jiang G, Chen Q and Zheng JN: Ki67
is a promising molecular target in the diagnosis of cancer
(review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yuan P, Xu B, Wang C, Zhang C, Sun M and
Yuan L: Ki-67 expression in luminal type breast cancer and its
association with the clinicopathology of the cancer. Oncol Lett.
11:2101–2105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Juríková M, Danihel Ľ, Polák Š and Varga
I: Ki67, PCNA, and MCM proteins: Markers of proliferation in the
diagnosis of breast cancer. Acta Histochem. 118:544–552. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Inwald EC, Klinkhammer-Schalke M,
Hofstädter F, Zeman F, Koller M, Gerstenhauer M and Ortmann O:
Ki-67 is a prognostic parameter in breast cancer patients: Results
of a large population-based cohort of a cancer registry. Breast
Cancer Res Treat. 139:539–552. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Denkert C, Budczies J, von Minckwitz G,
Wienert S, Loibl S and Klauschen F: Strategies for developing Ki67
as a useful biomarker in breast cancer. Breast. 24 (Suppl
2):S67–S72. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baek AE and Nelson ER: The contribution of
cholesterol and its metabolites to the pathophysiology of breast
cancer. Horm Cancer. 7:219–228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li JB and Jiang ZF: Chinese society of
clinical oncology breast cancer guideline version 2021: Updates and
interpretations. Zhonghua Yi Xue Za Zhi. 101:1835–1838. 2021.(In
Chinese). PubMed/NCBI
|
|
28
|
Perrotti F, Rosa C, Cicalini I, Sacchetta
P, Del Boccio P, Genovesi D and Pieragostino D: Advances in
lipidomics for cancer biomarkers discovery. Int J Mol Sci.
17:19922016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Szász AM, Győrffy B and Marko-Varga G:
Cancer heterogeneity determined by functional proteomics. Semin
Cell Dev Biol. 64:132–142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cappelletti V, Iorio E, Miodini P,
Silvestri M, Dugo M and Daidone MG: Metabolic footprints and
molecular subtypes in breast cancer. Dis Markers. 2017:76878512017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Monaco ME: Fatty acid metabolism in breast
cancer subtypes. Oncotarget. 8:29487–29500. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Eiriksson FF, Nøhr MK, Costa M,
Bödvarsdottir SK, Ögmundsdottir HM and Thorsteinsdottir M:
Lipidomic study of cell lines reveals differences between breast
cancer subtypes. PLoS One. 15:e2312892020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Furuta E, Okuda H, Kobayashi A and Watabe
K: Metabolic genes in cancer: Their roles in tumor progression and
clinical implications. Biochim Biophys Acta. 1805:141–152.
2010.PubMed/NCBI
|
|
34
|
Kim S, Lee Y and Koo JS: Differential
expression of lipid metabolism-related proteins in different breast
cancer subtypes. PLoS One. 10:e01194732015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kang HS, Lee SC, Park YS, Jeon YE, Lee JH,
Jung SY, Park IH, Jang SH, Park HM, Yoo CW, et al: Protein and
lipid MALDI profiles classify breast cancers according to the
intrinsic subtype. BMC Cancer. 11:4652011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ligorio F, Pellegrini I, Castagnoli L,
Vingiani A, Lobefaro R, Zattarin E, Santamaria M, Pupa SM, Pruneri
G, de Braud F and Vernieri C: Targeting lipid metabolism is an
emerging strategy to enhance the efficacy of anti-HER2 therapies in
HER2-positive breast cancer. Cancer Lett. 511:77–87. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zaidi N, Swinnen JV and Smans K:
ATP-citrate lyase: A key player in cancer metabolism. Cancer Res.
72:3709–3714. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Touvier M, Fassier P, His M, Norat T, Chan
DS, Blacher J, Hercberg S, Galan P, Druesne-Pecollo N and
Latino-Martel P: Cholesterol and breast cancer risk: A systematic
review and meta-analysis of prospective studies. Br J Nutr.
114:347–357. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Orho-Melander M, Hindy G, Borgquist S,
Schulz CA, Manjer J, Melander O and Stocks T: Blood lipid genetic
scores, the HMGCR gene and cancer risk: A Mendelian randomization
study. Int J Epidemiol. 47:495–505. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Beeghly-Fadiel A, Khankari NK, Delahanty
RJ, Shu XO, Lu Y, Schmidt MK, Bolla MK, Michailidou K, Wang Q,
Dennis J, et al: A Mendelian randomization analysis of circulating
lipid traits and breast cancer risk. Int J Epidemiol. 49:1117–1131.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Meng Y, Wang Q and Lyu Z: Cholesterol
metabolism and tumor. Zhejiang Da Xue Xue Bao Yi Xue Ban. 50:23–31.
2021.PubMed/NCBI
|
|
42
|
Ha M, Sung J and Song YM: Serum total
cholesterol and the risk of breast cancer in postmenopausal Korean
women. Cancer Causes Control. 20:1055–1060. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ehmsen S, Pedersen MH, Wang G, Terp MG,
Arslanagic A, Hood BL, Conrads TP, Leth-Larsen R and Ditzel HJ:
Increased cholesterol biosynthesis is a key characteristic of
breast cancer stem cells influencing patient outcome. Cell Rep.
27:3927–3938.e6. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fagherazzi G, Fabre A, Boutron-Ruault MC
and Clavel-Chapelon F: Serum cholesterol level, use of a
cholesterol-lowering drug, and breast cancer: Results from the
prospective E3N cohort. Eur J Cancer Prev. 19:120–125. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Goupille C, Ouldamer L, Pinault M,
Guimares C, Arbion F, Jourdan ML and Frank PG: Identification of a
positive association between mammary adipose cholesterol content
and indicators of breast cancer aggressiveness in a French
population. J Nutr. 151:1119–1127. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ni H, Liu H and Rong G: Serum lipids and
breast cancer risk: A meta-analysis of prospective cohort studies.
PLoS One. 10:e01426692015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Katzke VA, Sookthai D, Johnson T, Kühn T
and Kaaks R: Blood lipids and lipoproteins in relation to incidence
and mortality risks for CVD and cancer in the prospective
EPIC-Heidelberg cohort. BMC Med. 15:2182017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li X, Tang H, Wang J and Xie X, Liu P,
Kong Y, Ye F, Shuang Z, Xie Z and Xie X: The effect of preoperative
serum triglycerides and high-density lipoprotein-cholesterol levels
on the prognosis of breast cancer. Breast. 32:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kim Y, Park SK, Han W, Kim DH, Hong YC, Ha
EH, Ahn SH, Noh DY, Kang D and Yoo KY: Serum high-density
lipoprotein cholesterol and breast cancer risk by menopausal
status, body mass index, and hormonal receptor in Korea. Cancer
Epidemiol Biomarkers Prev. 18:508–515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Maiti B, Kundranda MN, Spiro TP and Daw
HA: The association of metabolic syndrome with triple-negative
breast cancer. Breast Cancer Res Treat. 121:479–483. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Fan Y, Ding X, Wang J, Ma F, Yuan P, Li Q,
Zhang P and Xu B: Decreased serum HDL at initial diagnosis
correlates with worse outcomes for triple-negative breast cancer
but not non-TNBCs. Int J Biol Markers. 30:e200–e207. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gallagher EJ, Zelenko Z, Neel BA, Antoniou
IM, Rajan L, Kase N and LeRoith D: Elevated tumor LDLR expression
accelerates LDL cholesterol-mediated breast cancer growth in mouse
models of hyperlipidemia. Oncogene. 36:6462–6471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Scheinman EJ, Rostoker R and Leroith D:
Cholesterol affects gene expression of the Jun family in colon
carcinoma cells using different signaling pathways. Mol Cell
Endocrinol. 374:101–107. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Hoque M, Rentero C, Conway JR, Murray RZ,
Timpson P, Enrich C and Grewal T: The cross-talk of LDL-cholesterol
with cell motility: Insights from the Niemann pick type C1 mutation
and altered integrin trafficking. Cell Adh Migr. 9:384–391. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Antalis CJ, Uchida A, Buhman KK and
Siddiqui RA: Migration of MDA-MB-231 breast cancer cells depends on
the availability of exogenous lipids and cholesterol
esterification. Clin Exp Metastasis. 28:733–741. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
dos Santos CR, Domingues G, Matias I,
Matos J, Fonseca I, de Almeida JM and Dias S: LDL-cholesterol
signaling induces breast cancer proliferation and invasion. Lipids
Health Dis. 13:162014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ye J, Xia X, Dong W, Hao H, Meng L, Yang
Y, Wang R, Lyu Y and Liu Y: Cellular uptake mechanism and
comparative evaluation of antineoplastic effects of
paclitaxel-cholesterol lipid emulsion on triple-negative and
non-triple-negative breast cancer cell lines. Int J Nanomedicine.
11:4125–4140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Catasus L, Gallardo A, Llorente-Cortes V,
Escuin D, Muñoz J, Tibau A, Peiro G, Barnadas A and Lerma E:
Low-density lipoprotein receptor-related protein 1 is associated
with proliferation and invasiveness in Her-2/neu and
triple-negative breast carcinomas. Hum Pathol. 42:1581–1588. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
van Duijnhoven FJ, Bueno-De-Mesquita HB,
Calligaro M, Jenab M, Pischon T, Jansen EH, Frohlich J, Ayyobi A,
Overvad K, Toft-Petersen AP, et al: Blood lipid and lipoprotein
concentrations and colorectal cancer risk in the European
prospective investigation into cancer and nutrition. Gut.
60:1094–1102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Borgquist S, Butt T, Almgren P, Shiffman
D, Stocks T, Orho-Melander M, Manjer J and Melander O:
Apolipoproteins, lipids and risk of cancer. Int J Cancer.
138:2648–2656. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zuo M, Rashid A, Wang Y, Jain A, Li D,
Behari A, Kapoor VK, Koay EJ, Chang P, Vauthey JN, et al: RNA
sequencing-based analysis of gallbladder cancer reveals the
importance of the liver X receptor and lipid metabolism in
gallbladder cancer. Oncotarget. 7:35302–35312. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zamanian-Daryoush M, Lindner D, Tallant
TC, Wang Z, Buffa J, Klipfell E, Parker Y, Hatala D,
Parsons-Wingerter P, Rayman P, et al: The cardioprotective protein
apolipoprotein A1 promotes potent anti-tumorigenic effects. J Biol
Chem. 288:21237–21252. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Han C, Zhang HT, Du L, Liu X, Jing J, Zhao
X, Yang X and Tian B: Serum levels of leptin, insulin, and lipids
in relation to breast cancer in China. Endocrine. 26:19–24. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chang SJ, Hou MF, Tsai SM, Wu SH, Hou LA,
Ma H, Shann TY, Wu SH and Tsai LY: The association between lipid
profiles and breast cancer among Taiwanese women. Clin Chem Lab
Med. 45:1219–1223. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Holm C, Rayala S, Jirström K, Stål O,
Kumar R and Landberg G: Association between Pak1 expression and
subcellular localization and tamoxifen resistance in breast cancer
patients. J Natl Cancer Inst. 98:671–680. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lin X, Hong S, Huang J, Chen Y, Chen Y and
Wu Z: Plasma apolipoprotein A1 levels at diagnosis are independent
prognostic factors in invasive ductal breast cancer. Discov Med.
23:247–258. 2017.PubMed/NCBI
|
|
67
|
Luporsi E, André F, Spyratos F, Martin PM,
Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B,
Arnould L, Gompel A, et al: Ki-67: Level of evidence and
methodological considerations for its role in the clinical
management of breast cancer: Analytical and critical review. Breast
Cancer Res Treat. 132:895–915. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Haroon S, Hashmi AA, Khurshid A,
Kanpurwala MA, Mujtuba S, Malik B and Faridi N: Ki67 index in
breast cancer: Correlation with other prognostic markers and
potential in pakistani patients. Asian Pac J Cancer Prev.
14:4353–4358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
de Azambuja E, Cardoso F, de Castro G Jr,
Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D,
Piccart-Gebhart MJ and Paesmans M: Ki-67 as prognostic marker in
early breast cancer: A meta-analysis of published studies involving
12,155 patients. Br J Cancer. 96:1504–1513. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Petrelli F, Viale G, Cabiddu M and Barni
S: Prognostic value of different cut-off levels of Ki-67 in breast
cancer: A systematic review and meta-analysis of 64,196 patients.
Breast Cancer Res Treat. 153:477–491. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Alco G, Bozdogan A, Selamoglu D, Pilanci
KN, Tuzlali S, Ordu C, Igdem S, Okkan S, Dincer M, Demir G and
Ozmen V: Clinical and histopathological factors associated with
Ki-67 expression in breast cancer patients. Oncol Lett.
9:1046–1054. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kanyilmaz G, Yavuz BB, Aktan M, Karaağaç
M, Uyar M and Fındık S: Prognostic importance of Ki-67 in breast
cancer and its relationship with other prognostic factors. Eur J
Breast Health. 15:256–261. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Soliman NA and Yussif SM: Ki-67 as a
prognostic marker according to breast cancer molecular subtype.
Cancer Biol Med. 13:496–504. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Hashmi AA, Hashmi KA, Irfan M, Khan SM,
Edhi MM, Ali JP, Hashmi SK, Asif H, Faridi N and Khan A: Ki67 index
in intrinsic breast cancer subtypes and its association with
prognostic parameters. BMC Res Notes. 12:6052019. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Mitrović O, Čokić V, Đikić D, Budeč M,
Vignjević S, Subotički T, Gulan M, Radović S and Furtula S:
Correlation between ER, PR, HER-2, Bcl-2, p53, proliferative and
apoptotic indexes with HER-2 gene amplification and TOP2A gene
amplification and deletion in four molecular subtypes of breast
cancer. Target Oncol. 9:367–379. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Ricoult SJH, Yecies JL, Ben-Sahra I and
Manning BD: Oncogenic PI3K and K-Ras stimulate de novo lipid
synthesis through mTORC1 and SREBP. Oncogene. 35:1250–1260. 2016.
View Article : Google Scholar : PubMed/NCBI
|
